Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a
biopharmaceutical company developing PRX302 (topsalysin) for the
treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged
prostate) and the treatment of localized prostate cancer, today
announced findings from an administrative interim analysis of efficacy
in its ongoing Phase 3 “PLUS-1” trial of PRX302 as a treatment for lower
urinary tract symptoms of BPH. The Independent Data Monitoring Committee
(IDMC) reported that a predefined efficacy threshold following treatment
was not achieved. This administrative interim analysis was conducted
specifically for planning subsequent clinical trials. The ongoing
“PLUS-1” study is unaffected by this recommendation, and all patients in
the study will continue to be followed to enable the evaluation of the
primary efficacy endpoint at 52 weeks.
“Patients will continue to be followed for the duration of the study to
evaluate the International Prostate Symptom Score (IPSS) total score
change from baseline over 52 weeks – the primary endpoint of the study,”
stated Randall Woods, President and CEO of Sophiris. “We expect to be
able to provide further commentary on the activity of PRX302 once the
study is complete and all the data through 52 weeks are unblinded and
analyzed in the fourth quarter of 2015.”
The IDMC completed the planned, protocol-specified administrative
analysis of efficacy based on the IPSS change from baseline to Week 12
for all 479 patients dosed in the study. Simultaneously with this
administrative interim efficacy analysis, the IDMC completed its fifth
and final periodic analysis of unblinded safety data and reported no
safety concerns to Sophiris. There were no events of sepsis reported
post administration of study drug in this trial.
The IDMC conveyed this recommendation to Sophiris in a manner that would
not unblind the study nor reveal the actual measured treatment effect.
Sophiris and others directly involved in the study will remain blinded
to treatment group assignment as the 52 week monitoring period continues
until after the last patient has completed the study, which is
anticipated to be in September 2015.
The Phase 3 “PLUS-1” study is an international, multicenter, randomized,
double-blind, and vehicle-controlled trial to assess the safety and
efficacy of a single intraprostatic administration of PRX302 (0.6 µg/g
prostate) for the treatment of BPH. Enrollment and dosing in the study
were completed in September 2014. The primary endpoint is the IPSS total
score change from baseline over 52 weeks. Secondary endpoints include
Qmax (maximum urine flow) change from baseline over 52 weeks.
About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a
clinical-stage, targeted therapy for the treatment of the symptoms of
BPH and treatment of low to intermediate risk localized prostate cancer.
PRX302 is in Phase 3 clinical development for the treatment of the
symptoms of BPH and is designed to be as efficacious as pharmaceuticals,
less invasive than the surgical interventions, and without the sexual
side effects seen with existing treatments. Sophiris plans to initiate a
Phase 2 proof of concept study of PRX302 for the treatment of localized
low to intermediate risk prostate cancer prior to the end of the first
quarter of 2015. For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered
forward looking, including any implied statements about the results of
the ongoing clinical trial of PRX302 or the efficacy of PRX302 and
statements in the CEO’s quote and plans related to other clinical
trials. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such
statements, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking
statements are based on Sophiris’ current beliefs as well as assumptions
made by and information currently available to Sophiris. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Due
to risks and uncertainties, including risks that the interim analysis
after three months from treatment may not be indicative of the final
results after 12 months from treatment, risks relating to the Company’s
ability to raise capital to fund an additional Phase 3 clinical trial
and the risks and uncertainties identified by Sophiris in its public
securities filings; actual events may differ materially from current
expectations. Sophiris disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Copyright Business Wire 2014